Stephen Slocum
Director, Drug Development, Project Lead LigaChem Biosciences Inc
Seminars
Tuesday 4th November 2025
Expanding ADC Therapeutic Index Through Site-Specific Bioconjugation & Tumor Selective Payload Release & Activation
11:30 am
- Discussing how LCB’s sitespecific ConjuAllTM platform enables discrete DAR ADCs with circulation stable bioconjugation
- Leveraging LCB’s proprietary beta-glucuronidase technology to enable unprecedented preclinical therapeutic indexes through tumor selective release and payload activation
- Assessing early clinical safety and efficacy across payload classes to validate the LCB platform
